A 52-year-old woman with rheumatoid arthritis has been taking naproxen 500 mg twice daily for 8 months with good disease control. She now presents with epigastric pain, nausea, and dark stools for 2 days. Her hemoglobin has dropped from 12.5 g/dL to 10.2 g/dL. Upper endoscopy reveals a 1.5 cm gastric ulcer with active bleeding (Forrest IIb). The ulcer is successfully treated with endoscopic hemostasis. What is the most appropriate next step in management?

Explanation

## NSAID-Induced Peptic Ulcer Bleeding: Management Algorithm This patient has **NSAID-induced peptic ulcer disease (PUD) with active bleeding**—a medical emergency requiring both acute hemostasis and prevention of recurrence. ### Acute Phase: Hemostasis (Already Completed) **Key Point:** Endoscopic therapy (injection, thermal coagulation, or clip placement) achieves hemostasis in >90% of cases. This patient has been successfully treated. ### Post-Hemostasis Management Strategy ```mermaid flowchart TD A[NSAID-induced PUD with bleeding - hemostasis achieved]:::outcome --> B{NSAID continuation necessary?}:::decision B -->|No - alternative available| C[Discontinue NSAID]:::action C --> D[Start PPI for 8 weeks]:::action D --> E[Test for H. pylori]:::action E --> F{H. pylori positive?}:::decision F -->|Yes| G[Triple/quadruple therapy]:::action F -->|No| H[Continue PPI, switch to non-NSAID analgesic]:::action B -->|Yes - essential for disease| I[Continue NSAID + PPI long-term]:::action I --> J[H. pylori testing]:::action ``` ### Rationale for Discontinuation in This Case | Factor | Consideration | |--------|---------------| | **Disease control** | Rheumatoid arthritis; alternatives exist (DMARDs, biologics, acetaminophen, topical agents) | | **Bleeding severity** | Active bleeding with hemoglobin drop; high recurrence risk if NSAID restarted | | **Risk stratification** | Age 52 + NSAID use + PUD history = very high risk for rebleeding | | **Guideline recommendation** | ACG/AGA: discontinue NSAID if alternative therapy available | **High-Yield:** In NSAID-induced PUD with bleeding, **discontinuation is preferred** unless the NSAID is irreplaceable (e.g., aspirin for secondary prevention post-MI). For rheumatoid arthritis, DMARDs and biologics are safer alternatives. ### If NSAID Continuation Were Necessary - **PPI + NSAID:** Long-term PPI (not H~2~-blocker) reduces ulcer recurrence from ~50% to ~5% - **COX-2 selective inhibitor + PPI:** Slightly lower GI risk than non-selective NSAID, but still requires PPI - **Misoprostol + NSAID:** Alternative gastroprotection (less commonly used now due to side effects) **Warning:** H~2~-blockers (ranitidine, famotidine) are **inferior to PPIs** for NSAID-induced ulcer prevention and should not be used as monotherapy in this setting. ### H. pylori Testing **Clinical Pearl:** H. pylori testing is mandatory even in NSAID-induced PUD because: - Dual pathology (NSAID + H. pylori) increases ulcer severity and recurrence risk - If H. pylori is present, eradication therapy (triple or quadruple regimen) is required - Testing should occur after PPI is started (may suppress organism; test after 2 weeks off PPI if initial test negative and clinical suspicion high) ### Post-Ulcer Analgesic Strategy for RA - **First-line:** Acetaminophen (up to 3 g/day) + DMARDs (methotrexate, biologics) - **Second-line:** Topical NSAIDs (diclofenac gel) for localized joint pain - **Third-line:** If NSAID essential: COX-2 selective inhibitor or non-selective NSAID + long-term PPI [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 297]